BioCentury | Mar 3, 2021
Product Development

Verdine’s FogPharma to bring lead cell-permeable peptide into clinic with $107M series C

...PagsGroup. Existing investors including GV, 6 Dimensions Capital, Deerfield...
BioCentury | Mar 2, 2021
Deals

March 1 Quick Takes: OrbiMed raises $3.5B for three funds; plus AZ-Junshi and megarounds for WuXi Diagnostics, FogPharma, Tenaya, DTx

...Associates, HBM Healthcare Investments, Casdin Capital and PagsGroup. Existing investors, including GV, 6 Dimensions Capital, Deerfield...
BioCentury | Feb 26, 2021
Deals

Feb. 25 Quick Takes: AveXis execs, Deerfield launch Jaguar plus one; Sarepta DMD approval, Apollomics IPO plans and Sirion-Sanofi, an Oxford pair and DeuterOncology

...executive chairman and Joe Nolan as CEO, the former management team of AveXis partnered with Deerfield...
...of autism spectrum disorder, Type I diabetes and, via subsidiary Axovia Therapeutics Inc., Bardet-Biedl syndrome. Deerfield...
...MET and RAS pathway inhibitor the company believes could overcome resistance to approved MET inhibitors. Jeff Cranmer AveXis Deerfield Apollomics Sarepta...
BioCentury | Feb 25, 2021
Deals

Feb. 24 Quick Takes: ICON buying PRA in $12B CRO deal; plus venture rounds for Yisheng, Xilio, Truvian, Lyvgen, AmacaThera, and more

...clinic this year. Rock Springs was joined by fellow new investors Bain Capital Life Sciences, Deerfield...
BioCentury | Feb 19, 2021
Emerging Company Profile

Frontier Medicines: tapping binding pockets across the proteome

...collaborators: UC BerkeleyCorporate partners: AbbVie Inc. (NYSE:ABBV)Number of employees: About 50Funds raised: $67 millionInvestors: MPM Capital, Deerfield...
BioCentury | Feb 18, 2021
Finance

Advent raises next funds, taps Midwest innovation

...VCs to enter formal arrangements with academic institutions, few have done so in the Midwest. Deerfield...
BioCentury | Jan 29, 2021
Finance

Jan. 28 Quick Takes: Sana aims high in latest IPO prospectus; plus short interest in biotech, and fundings for Curevac, Design, Ukko, Encodia and more

...of T. Rowe Price, Wellington Management, Avoro Capital Advisors, Vivo Capital and other, undisclosed investors.Northpond, Deerfield...
...company Encodia raised a $75 million series C round, with lead investors Northpond Ventures and Deerfield...
BioCentury | Jan 27, 2021
Emerging Company Profile

Nuvalent: Structure-based design to address selectivity, tumor resistance

...Emerging Company Profile: Out of stealth, Deerfield-backed Nuvalent prepares for clinic By Paul Bonanos, Associate Editor...
...in stealth mode during which it subsisted on a $50 million series A round from Deerfield...
...two targeted programs for non-small cell lung cancer.Nuvalent Inc.’s emergence represents the latest evidence of Deerfield...
BioCentury | Jan 15, 2021
Product Development

Paige to accelerate development, adoption of digital cancer diagnostic with $100M series C

...Capital and Johnson & Johnson Innovation – JJDC led Paige.AI Inc.’s financing, which also saw participation from Deerfield...
BioCentury | Jan 7, 2021
Finance

Werewolf’s conditionally-activated cancer therapies draw $72M series B, partnering interest

...roles at the Novartis Institutes for BioMedical Research (NIBR).Beyond RA Capital, Werewolf’s new series B investors include Deerfield...
Items per page:
1 - 10 of 1402
BioCentury | Mar 3, 2021
Product Development

Verdine’s FogPharma to bring lead cell-permeable peptide into clinic with $107M series C

...PagsGroup. Existing investors including GV, 6 Dimensions Capital, Deerfield...
BioCentury | Mar 2, 2021
Deals

March 1 Quick Takes: OrbiMed raises $3.5B for three funds; plus AZ-Junshi and megarounds for WuXi Diagnostics, FogPharma, Tenaya, DTx

...Associates, HBM Healthcare Investments, Casdin Capital and PagsGroup. Existing investors, including GV, 6 Dimensions Capital, Deerfield...
BioCentury | Feb 26, 2021
Deals

Feb. 25 Quick Takes: AveXis execs, Deerfield launch Jaguar plus one; Sarepta DMD approval, Apollomics IPO plans and Sirion-Sanofi, an Oxford pair and DeuterOncology

...executive chairman and Joe Nolan as CEO, the former management team of AveXis partnered with Deerfield...
...of autism spectrum disorder, Type I diabetes and, via subsidiary Axovia Therapeutics Inc., Bardet-Biedl syndrome. Deerfield...
...MET and RAS pathway inhibitor the company believes could overcome resistance to approved MET inhibitors. Jeff Cranmer AveXis Deerfield Apollomics Sarepta...
BioCentury | Feb 25, 2021
Deals

Feb. 24 Quick Takes: ICON buying PRA in $12B CRO deal; plus venture rounds for Yisheng, Xilio, Truvian, Lyvgen, AmacaThera, and more

...clinic this year. Rock Springs was joined by fellow new investors Bain Capital Life Sciences, Deerfield...
BioCentury | Feb 19, 2021
Emerging Company Profile

Frontier Medicines: tapping binding pockets across the proteome

...collaborators: UC BerkeleyCorporate partners: AbbVie Inc. (NYSE:ABBV)Number of employees: About 50Funds raised: $67 millionInvestors: MPM Capital, Deerfield...
BioCentury | Feb 18, 2021
Finance

Advent raises next funds, taps Midwest innovation

...VCs to enter formal arrangements with academic institutions, few have done so in the Midwest. Deerfield...
BioCentury | Jan 29, 2021
Finance

Jan. 28 Quick Takes: Sana aims high in latest IPO prospectus; plus short interest in biotech, and fundings for Curevac, Design, Ukko, Encodia and more

...of T. Rowe Price, Wellington Management, Avoro Capital Advisors, Vivo Capital and other, undisclosed investors.Northpond, Deerfield...
...company Encodia raised a $75 million series C round, with lead investors Northpond Ventures and Deerfield...
BioCentury | Jan 27, 2021
Emerging Company Profile

Nuvalent: Structure-based design to address selectivity, tumor resistance

...Emerging Company Profile: Out of stealth, Deerfield-backed Nuvalent prepares for clinic By Paul Bonanos, Associate Editor...
...in stealth mode during which it subsisted on a $50 million series A round from Deerfield...
...two targeted programs for non-small cell lung cancer.Nuvalent Inc.’s emergence represents the latest evidence of Deerfield...
BioCentury | Jan 15, 2021
Product Development

Paige to accelerate development, adoption of digital cancer diagnostic with $100M series C

...Capital and Johnson & Johnson Innovation – JJDC led Paige.AI Inc.’s financing, which also saw participation from Deerfield...
BioCentury | Jan 7, 2021
Finance

Werewolf’s conditionally-activated cancer therapies draw $72M series B, partnering interest

...roles at the Novartis Institutes for BioMedical Research (NIBR).Beyond RA Capital, Werewolf’s new series B investors include Deerfield...
Items per page:
1 - 10 of 1402